Neos Therapeutics, LP
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.8M
Doctors Paid
19,022
Transactions
99,245
2024 Total
$163,636
Payment Breakdown by Category
Food & Beverage$1.8M (37.1%)
Research$788,449 (16.5%)
Travel$292,768 (6.1%)
Consulting$62,975 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 974 | 38.9% |
| Food and Beverage | $1.8M | 96,704 | 37.1% |
| Unspecified | $788,449 | 472 | 16.5% |
| Travel and Lodging | $292,768 | 1,015 | 6.1% |
| Consulting Fee | $62,975 | 80 | 1.3% |
Payments by Type
General
$4.0M
98,773 transactions
Research
$788,449
472 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A single-dose, single-center, open-label, randomized, 5-arm, parallel study to assess the systematic exposure and safety of four modified-release orally disintegrating tablet formulations of NT0502 (N-desethyloxybutynin) and oxybutynin in healthy adults under fasted conditions - 4008579 (NT0502-1001) | $299,248 | 0 | 4 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | $202,439 | 12 | 355 |
| A single-dose, two-period, two-treatment, two-way crossover bioequivalence study of two formulations of methylphenidate extended-release orally disintegrating tablets (XR-ODT), 51.8 mg (2 X 25.9 mg) in healthy adults under fasted conditions. | $152,550 | 0 | 3 |
| An Open-Label, Single-Dose Pharmacokinetic Study of Cotempla XR ODT in Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | $104,603 | 0 | 107 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT- in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit-Hyperactivity Disorder -ADHD- | $29,518 | 0 | 2 |
| A Single-Dose, Three-Period, Three-Treatment, Three-Way Crossover Bioavailability Study of a Commercial Scale Formulation of NT0102 Methylphenidate Extended-Release Orally Disintegrating Tablets -XR-ODT- 60 mg -2 x 30 mg- under Fed and Fasted Conditions | $91.64 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Michael Feld, M.d, M.D | Psychiatry | Northbrook, IL | $264,447 | $0 |
| Dr. George Bright, M.d, M.D | Adolescent Medicine | Midlothian, VA | $251,195 | $0 |
| Dr. Gregg Friedman, Md, MD | Psychiatry | Hallandale Beach, FL | $99,012 | $0 |
| James Anderson, Md, MD | Pediatrics | High Point, NC | $89,847 | $0 |
| Matthew Brams, M.d, M.D | Child & Adolescent Psychiatry | Houston, TX | $63,801 | $0 |
| John Vaeth, Md, MD | Psychiatry | Baltimore, MD | $60,385 | $0 |
| Dr. Brian Barash, M.d, M.D | Psychiatry | Kansas City, MO | $57,398 | $0 |
| Dr. Frank Lopez, Md, MD | Neurodevelopmental Disabilities | Winter Park, FL | $56,712 | $0 |
| Dr. Alice Mao, Md, MD | Child & Adolescent Psychiatry | Houston, TX | $50,878 | $0 |
| Dr. William Dodson, M.d, M.D | Prescribing (Medical) | Greenwood Village, CO | $50,382 | $0 |
| Dr. Mark Ruggiero, M.d, M.D | Developmental - Behavioral Pediatrics | Truckee, CA | $50,273 | $0 |
| Dr. Birgit Amann, M.d, M.D | Child & Adolescent Psychiatry | Troy, MI | $49,807 | $0 |
| Unknown Provider | — | — | $46,222 | $0 |
| Maitri Patel, Md, MD | Child & Adolescent Psychiatry | Framingham, MA | $43,103 | $0 |
| Dr. Robert Hunt, M.d, M.D | Psychiatry | Nashville, TN | $42,218 | $0 |
| Dr. Divyansu Patel, M.d, M.D | Psychiatry | Austin, TX | $37,958 | $0 |
| Gregory Mattingly, M.d, M.D | Psychiatry | Saint Charles, MO | $34,675 | $0 |
| Theresa Cerulli, Md, MD | Psychiatry | North Andover, MA | $34,161 | $0 |
| Victor Evans, Md, MD | Child & Adolescent Psychiatry | Lexington, SC | $33,984 | $0 |
| Ann Childress | Child & Adolescent Psychiatry | Las Vegas, NV | $33,148 | $0 |
| Shiela Irick, Md, MD | Psychosomatic Medicine | Fishers, IN | $31,678 | $0 |
| Dr. Anthony Delach, Md, MD | Pediatrics | Orland Park, IL | $31,306 | $0 |
| Dr. Mark Owens, Do, DO | Psychiatry | Brooklyn, NY | $30,118 | $0 |
| Craig Kunins, M.d, M.D | Child & Adolescent Psychiatry | Gulfport, FL | $28,862 | $0 |
| Perry Roy, M.d, M.D | Internal Medicine | Charlotte, NC | $27,166 | $0 |
Ad
Top Products
- Adzenys XR-ODT $3.9M
- Cotempla XR-ODT $446,701
Associated Products (3)
- Adzenys XR-ODT $3.9M
- Cotempla XR-ODT $447,045
- COTEMPLA XR-ODT $39,690
Payment Categories
- Food & Beverage $1.8M
- Consulting $62,975
- Travel & Lodging $292,768
- Research $788,449
About Neos Therapeutics, LP
Neos Therapeutics, LP has made $4.8M in payments to 19,022 healthcare providers, recorded across 99,245 transactions in the CMS Open Payments database. In 2024, the company paid $163,636. The top product by payment volume is Adzenys XR-ODT ($3.9M).
Payments were distributed across 187 medical specialties. The top specialty by payment amount is Psychiatry ($1.5M to 2,996 doctors).
Payment categories include: Food & Beverage ($1.8M), Consulting ($62,975), Research ($788,449), Travel & Lodging ($292,768).
Neos Therapeutics, LP is associated with 3 products in the CMS Open Payments database.